CN106102767B - 用于诊断和治疗炎症性肠病的方法 - Google Patents

用于诊断和治疗炎症性肠病的方法 Download PDF

Info

Publication number
CN106102767B
CN106102767B CN201580016240.3A CN201580016240A CN106102767B CN 106102767 B CN106102767 B CN 106102767B CN 201580016240 A CN201580016240 A CN 201580016240A CN 106102767 B CN106102767 B CN 106102767B
Authority
CN
China
Prior art keywords
hvr
mrna
seq
patient
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580016240.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106102767A (zh
Inventor
J·A·哈克尼
M·凯伊尔
G·W·特乌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202110901698.4A priority Critical patent/CN113604543A/zh
Publication of CN106102767A publication Critical patent/CN106102767A/zh
Application granted granted Critical
Publication of CN106102767B publication Critical patent/CN106102767B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580016240.3A 2014-03-27 2015-03-26 用于诊断和治疗炎症性肠病的方法 Expired - Fee Related CN106102767B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110901698.4A CN113604543A (zh) 2014-03-27 2015-03-26 用于诊断和治疗炎症性肠病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971379P 2014-03-27 2014-03-27
US61/971,379 2014-03-27
PCT/US2015/022762 WO2015148809A1 (en) 2014-03-27 2015-03-26 Methods for diagnosing and treating inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110901698.4A Division CN113604543A (zh) 2014-03-27 2015-03-26 用于诊断和治疗炎症性肠病的方法

Publications (2)

Publication Number Publication Date
CN106102767A CN106102767A (zh) 2016-11-09
CN106102767B true CN106102767B (zh) 2021-08-10

Family

ID=54196399

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580016240.3A Expired - Fee Related CN106102767B (zh) 2014-03-27 2015-03-26 用于诊断和治疗炎症性肠病的方法
CN202110901698.4A Pending CN113604543A (zh) 2014-03-27 2015-03-26 用于诊断和治疗炎症性肠病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110901698.4A Pending CN113604543A (zh) 2014-03-27 2015-03-26 用于诊断和治疗炎症性肠病的方法

Country Status (15)

Country Link
US (4) US10273542B2 (enExample)
EP (1) EP3122377A4 (enExample)
JP (3) JP7054990B2 (enExample)
KR (2) KR20220065091A (enExample)
CN (2) CN106102767B (enExample)
AR (1) AR099856A1 (enExample)
AU (3) AU2015235986B2 (enExample)
BR (1) BR112016020053A2 (enExample)
CA (1) CA2939246A1 (enExample)
IL (2) IL247266B (enExample)
MA (1) MA39804A (enExample)
MX (2) MX2016012282A (enExample)
RU (1) RU2016136716A (enExample)
SG (1) SG11201607938UA (enExample)
WO (1) WO2015148809A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255508A1 (en) * 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
MA39804A (fr) 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
JP2018507868A (ja) * 2015-02-26 2018-03-22 ジェネンテック， インコーポレイテッド インテグリンベータ７アンタゴニスト及びクローン病の治療方法
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CN107083423B (zh) * 2017-03-27 2022-01-28 北京极客基因科技有限公司 一种药物靶点预测和药物全方面评价方法
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
EP3884276A2 (en) * 2018-11-23 2021-09-29 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
RS66976B1 (sr) 2019-10-16 2025-07-31 Morphic Therapeutic Inc Inhibiranje ljudskog integrina alfa4beta7
US12394524B2 (en) * 2020-07-22 2025-08-19 Iterative Scopes, Inc. Systems and methods for analysis of medical images for scoring of inflammatory bowel disease
EP4188958A1 (en) 2020-07-31 2023-06-07 Genentech, Inc. Anti-integrin beta7 antibody formulations and devices
GB2616129A (en) * 2020-09-01 2023-08-30 Scipher Medicine Corp Methods and systems for predicting response to anti-TNF therapies
EP4467573A4 (en) * 2021-10-15 2025-08-06 Yichen Therapeutics Ltd BISPECIFIC BINDING MOLECULE
CN114085908B (zh) * 2021-10-30 2023-08-08 中国人民解放军陆军军医大学第一附属医院 用于评估胶质母细胞瘤治疗效果的基因靶点组合及其应用
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026759A3 (en) * 2004-09-03 2006-10-05 Genentech Inc Humanized anti-beta7 antagonists and uses therefor

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4256833A (en) 1979-01-08 1981-03-17 Majid Ali Enzyme immunoassay for allergic disorders
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
AU652540B2 (en) 1989-07-19 1994-09-01 Xoma Corporation T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
MXPA02010507A (es) 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005009339A2 (en) * 2003-05-30 2005-02-03 Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) Inflammatory bowel diseases
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
WO2007067912A2 (en) * 2005-12-07 2007-06-14 Boehringer Ingelheim International Gmbh Treatment and diagnostics of inflammatory diseases
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
WO2008028031A2 (en) * 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
WO2008088849A2 (en) * 2007-01-16 2008-07-24 Wyeth Inflammation treatment, detection and monitoring via trem-1
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
TW200848431A (en) * 2007-06-12 2008-12-16 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
BRPI0820707A2 (pt) 2007-11-07 2015-06-16 Genentech Inc Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
AU2009215441B2 (en) * 2008-02-19 2015-07-02 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
US20110117111A1 (en) * 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100255508A1 (en) * 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2347256A4 (en) * 2008-10-09 2012-02-08 Alfagene Bioscience Inc USE AND IDENTIFICATION OF BIOMARKERS FOR GASTROINTESTINAL DISEASES
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
CA2758531C (en) * 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
AU2010276392A1 (en) * 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US8766034B2 (en) * 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
EP2668287B1 (en) * 2011-01-25 2017-09-06 TC LAND Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody
CN109734807A (zh) 2011-03-31 2019-05-10 豪夫迈·罗氏有限公司 施用β7整联蛋白拮抗剂的方法
US20130040835A1 (en) * 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
CN102876793B (zh) * 2012-09-29 2014-03-12 山东省皮肤病性病防治研究所 单核苷酸多态性rs2058660在检测麻风病易感基因中的应用
CN102876794B (zh) * 2012-09-29 2014-07-02 山东省皮肤病性病防治研究所 单核苷酸多态性rs6871626在检测麻风病易感基因中的应用
AU2013326921C1 (en) 2012-10-05 2018-01-18 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
EP3495814A3 (en) 2013-03-27 2019-07-17 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
MA39804A (fr) 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026759A3 (en) * 2004-09-03 2006-10-05 Genentech Inc Humanized anti-beta7 antagonists and uses therefor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A Role of a Lymphocyte Tryptase, Granzyme A, in Experimental Ulcerative Colitis;Hirofumi HIRAYASU 等;《Bioscience, Biotechnology, and Biochemistry》;20070107;第71卷(第1期);第234-237页 *
Activated CD4+ and CD8+ Cytotoxic Cells Are Present in Increased Numbers in the Intestinal Mucosa from Patients with Active Inflammatory Bowel Disease;Stefan Muller 等;《American Journal of Pathology》;19980131;第152卷(第1期);第261-268页 *
AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis;M. Keir 等;《Journal of Crohn’s and Colitis》;20140228;第8卷(第1期);第S6-S7页 *
Association Between Response to Etrolizumab and Expression of Integrin aE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis;Gaik W. Tew 等;《Gastroenterology》;20161231;第150卷(第2期);第477-487页 *
Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA Microarrays;Christine M. Costello 等;《PLoS Med》;20050823;第2卷(第8期);第0771-0787页 *
Expression of the Vanin Gene Family in Normal and Inflamed Human Skin: Induction by Proinflammatory Cytokines;Patrick A.M. Jansen 等;《Journal of Investigative Dermatology》;20090326;第129卷;第2167-2174页 *
Mucosal biomarkers in inflammatory bowel disease: Key pathogenic players or disease predictors?;Franco Scaldaferri 等;《World J Gastroenterol》;20100607;第16卷(第21期);第2616-2625页 *
TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating Both T-Helper 1 and T-Helper 17 Activation;HIDETOSHI TAKEDATSU 等;《GASTROENTEROLOGY》;20080831;第135卷(第2期);第552-567页 *
TNFSF15 is an Ethnic Specific IBD Gene;Yoana Picornell 等;《Inflamm Bowel Dis》;20071130;第13卷(第11期);第1333-1338页 *

Also Published As

Publication number Publication date
JP2017511131A (ja) 2017-04-20
AU2021200518A1 (en) 2021-02-25
RU2016136716A (ru) 2018-04-28
AU2021203296A1 (en) 2021-06-17
AU2021200518B2 (en) 2021-03-04
US20190256913A1 (en) 2019-08-22
JP2020062013A (ja) 2020-04-23
EP3122377A4 (en) 2018-03-14
US10273542B2 (en) 2019-04-30
MA39804A (fr) 2017-02-01
KR20160130780A (ko) 2016-11-14
BR112016020053A2 (pt) 2018-02-20
AU2015235986A1 (en) 2016-08-25
IL276516A (en) 2020-09-30
US20200325538A1 (en) 2020-10-15
IL247266A0 (en) 2016-09-29
AU2015235986B2 (en) 2020-12-03
US11261493B2 (en) 2022-03-01
EP3122377A1 (en) 2017-02-01
US20220186314A1 (en) 2022-06-16
WO2015148809A1 (en) 2015-10-01
JP7054990B2 (ja) 2022-04-15
SG11201607938UA (en) 2016-10-28
CN113604543A (zh) 2021-11-05
US20170233809A1 (en) 2017-08-17
MX2016012282A (es) 2017-01-06
KR102397324B1 (ko) 2022-05-13
MX2022010809A (es) 2022-09-27
CN106102767A (zh) 2016-11-09
JP2022043033A (ja) 2022-03-15
KR20220065091A (ko) 2022-05-19
CA2939246A1 (en) 2015-10-01
AR099856A1 (es) 2016-08-24
IL247266B (en) 2020-08-31
US10669587B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
CN106102767B (zh) 用于诊断和治疗炎症性肠病的方法
US11091551B2 (en) Methods for diagnosing and treating inflammatory bowel disease
CN108139385A (zh) 用于诊断和治疗炎症性肠病的方法
HK40059862A (en) Methods for diagnosing and treating inflammatory bowel disease
HK1230521A1 (en) Methods for diagnosing and treating inflammatory bowel disease
HK1230521B (zh) 用於诊断和治疗炎症性肠病的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230521

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210810